<DOC>
	<DOCNO>NCT00077779</DOCNO>
	<brief_summary>The purpose study test whether Adalimumab ( two different dos ) induce maintain clinical remission subject active Crohn 's disease compare placebo ( substance contain medication )</brief_summary>
	<brief_title>Adalimumab Induction Maintenance Clinical Remission Subjects With Crohn 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Inclusion : Males female age 18 75 diagnosed moderate severe Crohn 's Disease define CDAI score &gt; = 220 &lt; = 450 , normal laboratory parameter , willing able give inform consent , able selfinject designee healthcare professional inject study medication . Exclusion : History certain type cancer , diagnosis ulcerative colitis , female breast feeding subject , surgical bowel resection ( ) past 6 month , history listeria , human immunodeficiency virus ( HIV ) , central nervous system demyelinate disease untreated TB , history poorly control medical condition , unsuccessful response infliximab antiTNF agent use past .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2007</verification_date>
</DOC>